Meeting
2020 ASCO Virtual Scientific Program
X versus XELOX versus PF in definitive concurrent chemoradiotherapy (DCRT) for local advanced squamous esophageal cancer (ESCC): Update from a multicenter, open-label, randomized III trial, CRTCOESC trial.
Authors
Ruinuo Jia
Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China
Ruinuo Jia , Tanyou Shan , Lixin Wan , Anping Zheng , Shuang Hui , Zhiqiao Xu , Feng Wang , Guobao Zheng , Ping Lu , Guifang Zhang , Yingjuan Zheng , Yanhui Cui , Xiaoyong Luo , Weiguo Zhang , Wanying Li , Ruonan Li , Fuyou Zhou , Shegan Gao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02025036
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4531)
DOI
10.1200/JCO.2020.38.15_suppl.4531
Abstract #
4531
Poster Bd #
139
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma.
First Author: Harry H. Yoon
Poster
2019 ASCO Annual Meeting
A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).
First Author: Jian-Ming Xu
Poster
2017 ASCO Annual Meeting
A randomized, open-label, multicenter trial of the concurrent chemoradiotherapy of capecitabine with or without oxaliplatin versus cisplatin with 5-FU for Chinese squamous esophageal cancer: An interim report from CRTCOESC.
First Author: Ruinuo Jia
Poster
2016 Gastrointestinal Cancers Symposium
Phase II trial of bolus 5-FU/l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant unresectable gastric cancer (HGCSG1502).
First Author: Tetsuhito Muranaka